Comparison of S‑1–cisplatin every 5 weeks with capecitabine‑cisplatin every 3 weeks for HER2‑negative gastric cancer (recurrent after S‑1 adjuvant therapy or chemotherapy‑naïve advanced): pooled analysis of HERBIS‑2 (OGSG 1103) and HERBIS‑4A (OGSG 1105) trials

Docetaxel plus S‑1 versus cisplatin plus S‑1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS‑3)

Phase II Study of Panitumumab Monotherapy in Chemotherapy- Naive Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer OGSG 1602

高度リンパ節転移を伴う進行胃癌に対する術前カペシタビン＋ シスプラチン療法第Ⅱ相臨床試験（OGSG1401)

A phase II trial of dose‑reduced nab‑paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)

Phase II study of capecitabine plus oxaliplatin in patients with gastric cancer resistant/intolerable to CDDP (OGSG1403)

A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302)

Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG1602）

Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2 negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: a pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials

Phase II study of preoperative radiotherapy combined with S-1 plus cisplatin in clinically resectable type 4 or large type 3 gastric cancer （OGSG1205）